Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Capricor will start a Phase II trial in the first quarter of 2018 for its regenerative cell therapy CAP-1002 in Duchenne muscular dystrophy following positive results in an early-stage trial – the stem cell product was dropped by Capricor's big pharma partner Johnson & Johnson earlier this year.
Boehringer Ingelheim is seeking partners with early-stage, novel approaches to neuropsychiatry disorders under its strategy of applying "fresh thinking" to diseases of the central nervous system with high unmet need.
From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.
Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.
Sanofi Pasteur's R&D chief talks to Scrip about the integration process for Protein Sciences, a vaccine company the group acquired earlier this year in a $650m deal, and how Sanofi Pasteur is using new technologies to speed up vaccine development.
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.